Targeted or empiric therapy for gram positive infections including skin and soft tissue, and pneumonia.
Covers MRSA and VRE
CBC with differential at least once/week.
Visual testing for therapy greater than 1 month or if symptoms develop on therapy.
Myelosuppression (usually with >2weeks therapy)- reversible, most common thrombocytopenia and neutropenia
Peripheral/optic neuropathy with prolonged courses (> 28 days). Any symptoms of visual change or impairment warrant immediate ophthalmic evaluation and possible discontinuation of therapy
Elevated liver enzymes
SSRI and other serotonergics/MAOIs- increased risk of serotonin syndrome (agitation, confusion, hallucinations, hyperreflexia, myoclonus, shivering, sweating and tachycardia)
Rifampin decreases linezolid levels.
Antimicrobial class: Oxazolidinone
Average serum half life:
Preterm neonates <1 week: 5.6 hours
Full-term neonates < 1 week : 3 hours
Full-term neonates ≥1 week to ≤ 28 days: 1.5 hours
Infants > 28 days to < 3 months: 1.8 hours
Infants and Children 3 months to 11 years: 2.9 hours
Adolescents: 4.1 hours
Adults: 4.9 hours
Route of Elimination:
Urine (~30% of total dose as parent drug, ~50 of total dose as inactive metabolites), two metabolites may accumulate in patients with severe renal impairment
Feces (9% of total dose as metabolites)